End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain-Reference-Cited by-同舟云学术

End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain

Published:2024-05 Issue:5 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Whitaker Heather J.¹^ORCID,Willam Naoma²,Cottrell Simon³,Goudie Rosalind⁴,Andrews Nick⁵,Evans Josie²,Moore Catherine⁶,Agrawal Utkarsh⁴,Hassell Katie⁵,Gunson Rory⁷,Zitha Jana³^ORCID,Anand Sneha⁴,Sebastian‐Pillai Praveen⁸,Kalapotharakou Panoraia³,Okusi Cecilia⁴,Hoschler Katja⁸,Jamie Gavin⁴^ORCID,Kele Beatrix⁸^ORCID,Hamilton Mark²,Couzens Anastasia⁶,Quinot Catherine⁵,Pheasant Kathleen⁶,Byford Rachel⁴,Marsh Kimberly²,Robertson Chris⁹,de Lusignan Simon⁴¹⁰,Williams Christopher³,Zambon Maria⁸,McMenamin Jim²,Watson Conall H.⁵

Affiliation:

1. Statistics, Modelling and Economics Department UK Health Security Agency London UK

2. Clinical and Protecting Health Public Health Scotland Glasgow UK

3. Public Health Wales Communicable Disease Surveillance Centre Public Health Wales Cardiff UK

4. Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK

5. Immunisation and Vaccine Preventable Diseases Division UK Health Security Agency London UK

6. Wales Specialist Virology Centre Public Health Wales Microbiology Cardiff UK

7. West of Scotland Specialist Virology Centre NHS Greater Glasgow and Clyde Glasgow UK

8. Respiratory Virus Unit UK Health Security Agency London UK

9. Department of Mathematics and Statistics University of Strathclyde Glasgow UK

10. Research and Surveillance Centre Royal College of General Practitioners London UK

Abstract

ABSTRACTBackgroundThe 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.MethodsEnd‐of‐season adjusted vaccine effectiveness (VE) estimates against sentinel primary‐care attendance for influenza‐like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.MethodsResults In the mainland United Kingdom, end‐of‐season VE against all laboratory‐confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell‐based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).ConclusionThe paper provides evidence of moderate influenza VE in 2022/23.

Funder

Public Health Scotland

Public Health Wales

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13295

Reference28 articles.

1. UK Health Security Agency “Surveillance of Influenza and Other Seasonal Respiratory Viruses in Winter 2021 to 2022 ” UK Health Security Agency 30/09/2022 (2022) https://www.gov.uk/government/statistics/annual‐flu‐reports/surveillance‐of‐influenza‐and‐other‐seasonal‐respiratory‐viruses‐in‐winter‐2021‐to‐2022.

2. Public Health England “Surveillance of Influenza and Other Seasonal Respiratory Viruses in the UK: Winter 2020 to 2021 ” (2021) https://webarchive.nationalarchives.gov.uk/ukgwa/20220401215804mp_/https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/995284/Surveillance_of_influenza_and_other_seasonal_respiratory_viruses_in_the_UK_2020_to_2021‐1.pdf.

3. UK Health Security Agency “Surveillance of Influenza and Other Seasonal Respiratory Viruses in the UK Winter 2022 to 2023 ” (2023) https://www.gov.uk/government/statistics/annual‐flu‐reports/surveillance‐of‐influenza‐and‐other‐seasonal‐respiratory‐viruses‐in‐the‐uk‐winter‐2022‐to‐2023.

4. Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19

5. Department of Health and Social Care “National Flu Immunisation Programme 2022 to 2023 Letter ” (2022) https://webarchive.nationalarchives.gov.uk/ukgwa/20230515154700/https://www.gov.uk/government/publications/national‐flu‐immunisation‐programme‐plan/national‐flu‐immunisation‐programme‐2022‐to‐2023‐letter.